GEOGRAPHIC ATROPHY

This study tests an experimental medicine called BI 1584862 in 150 adults aged 50 and older with geographic atrophy, a progressive eye disease that causes blind spots. Participants receive either the drug or a placebo for one year, and doctors track changes in the retina using sp…

This study tests a new medicine, BI 771716, against an existing treatment (pegcetacoplan) for geographic atrophy, a progressive eye disease that causes vision loss. About 202 adults aged 50 and older will receive eye injections every 4 weeks for just over a year. The goal is to s…

This study looks at the safety and how doctors use Syfovre (pegcetacoplan) in routine care for 300 people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. Participants receive the drug as prescribed by their doctor, and researc…

This study tests a new gene therapy called OCU410 for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. The trial involves up to 60 participants aged 50 and older and aims to check the treatment's safety and whether …

This study tests an experimental drug called tinlarebant in 429 adults with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. Participants receive either the drug or a placebo for about two years. The main goal is to see if the …

This study tests whether monthly eye injections of a drug called ANX007 can prevent significant vision loss in people with dry age-related macular degeneration (AMD) that has progressed to geographic atrophy. About 659 participants receive either the drug or a sham injection. The…

This study planned to test a smaller, new-generation telescope implant for people with severe central vision loss from advanced age-related macular degeneration (AMD). The goal was to check safety, especially how the implant affects cells on the back of the cornea. However, the s…

This early-stage study tests an experimental drug called Kamuvudine-8 (K8) for people with geographic atrophy, a form of advanced dry age-related macular degeneration that causes vision loss. About 30 participants will receive eye injections and be monitored for 26 weeks to check…

This early-stage study tests the safety of an experimental drug called RO7669330, given as an eye injection, for people with geographic atrophy (a severe form of dry age-related macular degeneration). The study involves 27 participants and will monitor side effects and eye health…

This early-stage study tests whether a device that uses real-time sound feedback can help people with vision loss keep their eyes still during eye imaging. Researchers will compare how steady participants' eyes are with and without the sound cues. The goal is to improve the quali…